Navigation Links
HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
Date:3/6/2013

SAN DIEGO, March 6, 2013 /PRNewswire/ -- HUYA Bioscience International announced today a collaborative partnership with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. and Shanghai Pharma Engine Co. Ltd. (collectively, "Zhangjiang Biotech Pharmaceutical Base").  HUYA is an international leader in accelerating the global development of China's pharmaceutical innovations.  This new partnership will focus on innovations coming out of companies located in Zhangjiang Biotech Pharmaceutical Base that could meet critical global pharmaceutical pipeline needs.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing both preclinical and clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

Founded in 1996 and supported jointly by the Ministry of Science and Technology, the Ministry of Health, SFDA, Chinese Academy of Sciences and Shanghai Municipal Government, Zhangjiang Biotech Pharmaceutical Base focuses on the development of innovations in biotechnology and pharmaceutical industries.   As the core district of Shanghai National Bio-Industry Base with the nickname "Zhangjiang Pharmaceutical Valley", after more than 15 years of development it has attracted more than 300 life science companies, research institutes and related service organizations, both domestic and international, and formed a comprehensive bio-pharmaceutical innovation system and industrial clusters.

The partnership will enable HUYA and Zhangjiang Biotech Pharmaceutical Base to collaborate on promoting new drug development worldwide.  Zhangjiang Biotech Pharmaceutical Base will be able to consult with HUYA's team of experts in drug development and globalization.  In turn, HUYA will have the first opportunity to evaluate certain research and development projects conducted at Zhangjiang Biotech Pharmaceutical Base and provide support and assistance as needed.

"HUYA is delighted to work with the prestigious Zhangjiang Biotech Pharmaceutical Base in a partnership that aims to advance the global development of innovative pharmaceutical products from China," said Clement Gingras , HUYA's Chief Technical Officer and COO, China.  "We are very excited about this partnership and look forward to fruitful collaborations in the years to come." 

Senior management of Zhangjiang Biotech Pharmaceutical Base also expressed optimism about this collaboration:  "Our goal is to become a top-rank pharmaceutical development base in Asia, and build a world-renowned biomedical innovation platform.  We hope that HUYA will help accelerate the global reach of innovations originated from 'Zhangjiang Pharmaceutical Valley' by providing expertise on global pharmaceutical development." 

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is the leader in global pharmaceutical co-development with Chinese partners. With eight offices strategically located across China, the most comprehensive Chinese compound database in the world, and a growing number of collaboration agreements with premier Chinese research and development organizations, HUYA occupies a unique position with regards to the China bio-pharmaceutical industry.  Its strategy to identify and license novel Chinese compounds, and to offer Western pharmaceutical companies efficient and comprehensive access to therapeutic innovation in China, means the company can enable efficient global development.  HUYA has become a champion in guiding China's biomedical innovations into the worldwide marketplace.  HUYA is jointly headquartered in Shanghai and in San Diego, California.  More information is available at www.huyabio.com.

ABOUT ZHANGJIANG BIOTECH PHARMACEUTICAL BASE

Since the establishment of State Biotech and Pharmaceutical Industrial Base (Shanghai) in Zhangjiang in 1996 and implementation of the strategic policy of "Focus on Zhangjiang", Zhangjiang Biotech Pharmaceutical Base has gone through tremendous growth and now houses more than 300 institutions and enterprises, including national research institutes, R&D headquarters of multinational pharmaceutical companies, many domestic pharmaceutical companies, CROs, and public service platforms.  It has become one of the landmark biopharma park and industrial cluster, known for having the highest density of research and development institutions, the highest capability for innovation and the most prominent result for new drug development in China. More information is available at http://www.zjbpb.com/web/index.asp.

Shanghai Pharma Engine Co., Ltd, a wholly owned subsidiary of Zhangjiang Biotech and Pharmaceutical Base Development Co., is a state-level biopharmaceutical incubator, providing technical, contract research and investment consultation services.  More information is available at http://www.zhangjiang.net/tabid/182/ArticleID/462/Default.aspx.

CONTACT

Clement Gingras
CTO and COO, China
HUYA Bioscience International
+1.858.798.8800
cgingras@huyabio.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
2. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
3. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
4. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
5. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
6. Dr. Susan Froshauer to join Connecticut bioscience team at CURE
7. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
8. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
9. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology:
(Date:4/29/2017)... Baltimore, MD (PRWEB) , ... April 29, 2017 , ... ... noisy jobs, so what are Americans doing in their leisure time that causes hearing ... assess lifestyle habits that may be contributing to hearing loss, as well as schedule ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield ... credit rating of “A” and its outlook as “stable.” At the same time, the ... have fallen in recent years, dip below “capital adequacy” thresholds required for its strong ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... Texas (PRWEB) , ... April 28, 2017 , ... The ... plaque in recently to the labor and delivery team at Women’s Hospital at Renaissance ... mothers who give birth at the hospital and decide to donate. , “Women’s ...
Breaking Medicine News(10 mins):